Medpace

Last updated
Medpace Holdings, Inc.
FormerlyMedical Research Services (1992-bef.2014)
Company type Public
Industry Contract Research Organization
Founded1992;32 years ago (1992)
Headquarters Cincinnati, Ohio, U.S.
Area served
Increase2.svg Over 40 countries (2023) [1]
Key people
August J. Troendle (CEO & Chairman of the Board of Directors)
ProductsSupport services for pharmaceutical, biotech, and medical device companies
Revenue US$1.46 billion (2022) [1]
Number of employees
Increase2.svg 5,400 (2023) [1]
Website medpace.com

Medpace Holdings, Inc. (alt. Medpace) is a global clinical research organization (CRO) based in Cincinnati, Ohio, [2] [1] [3] employing approximately 5,400 people. Medpace's mission statement is "to accelerate the global development of safe and effective medical therapeutics" through its high science and disciplined operating approach that leverages local, regulatory, and deep therapeutic expertise across all major areas, including oncology, cardiology, metabolic disease, endocrinology, central nervous system, and anti-viral and anti-infective. Operating under a full-service model, Medpace provides a therapeutically focused, integrated, global approach to clinical development. The company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.

Contents

The company started trading stock as a public firm in 2016.

History

August Troendle founded Medpace in Cincinnati, Ohio in 1992 as Medical Research Services. [4] Troendle first became interested in the CRO sector after working in both the regulatory and pharmaceutical area. He began his career as a reviewer with the FDA, specializing in the development of lipid lowering therapies to treat high cholesterol.

With a team of industry physicians, Jonathan Issacsohn and Evan Stein completed many early studies while at Medpace and Medpace Reference Laboratories on the use of statin therapies for the treatment of hypercholesterolemia. [5] Another Medpace physician, David Orloff was regarded as an industry opinion leader in the study of metabolic diseases - most specifically diabetes and obesity. [6] Troendle was honored for his work as a Medpace founder in 2012 by the Cincinnati Chamber of Commerce. [7]

Medpace completed construction on a new campus in 2012 in Madisonville, a neighborhood on the eastern side of Cincinnati. [8] The project encompassed revitalizing an urban brownfield site formerly occupied by NuTone, and creating a state of the art LEED (Leadership in Energy and Environmental Design) certified campus. [9]

In 2022, Medpace announced a $150 million capital investment to expand its headquarters in Cincinnati, Ohio adding an estimated expansion of 1,500 new jobs.

Acquisitions

Ownership

In 2011, CCMP Capital acquired 80% of the firm for US$285 million. [14] Three years later, in February 2014, CCMP auctioned their 80% stake; the winner was won by Cinven, who paid US$900 million. [4] [14] In August 2017, Medpace went became a publicly-traded company with its initial public offering, selling 8,050,000 shares of common stock. [4]

Recognition

In 2021, Medpace was named a 2021 SCRS Eagle Award finalist. The SCRS Eagle Award honors one Sponsor and one CRO that exemplifies a site-focused approach to clinical trial management and has demonstrated outstanding leadership, professionalism, integrity, passion, and dedication to advancing the clinical research profession through strong site partnerships. Also, in 2021, Medpace was recently ranked 10 in the 2021 LinkedIn Top 10 Companies in Cincinnati and Forbes America’s Best Mid-size Companies. These rankings measure important elements of career progression, including advancement, skills growth, company stability, external opportunity, company affinity, gender diversity, and educational background.

In 2023, Medpace has been recognized with 5 CRO Leadership Awards for reliability, quality, expertise, compatibility, and capabilities. 46 contract research organizations were assessed on 20+ performance metrics in ISR’s annual CRO Quality Benchmarking survey to determine the CROs that meet or exceed their customers’ expectations.

Further reading

Related Research Articles

<span class="mw-page-title-main">Huntingdon Life Sciences</span> Contract research organisation

Huntingdon Life Sciences (HLS) was a contract research organisation (CRO) founded in 1951 in Cambridgeshire, England. It had two laboratories in the United Kingdom and one in the United States. With over 1,600 staff, it was until 2015 the largest non-clinical CRO in Europe. In September 2015, Huntingdon Life Sciences, Harlan Laboratories, GFA, NDA Analytics and LSR associates merged into Envigo, which later sold off the CRO part.

<span class="mw-page-title-main">Roche</span> Swiss multinational healthcare company

F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76.

<span class="mw-page-title-main">Labcorp Drug Development</span> Contract research organization

Labcorp Drug Development is a contract research organization headquartered in Burlington, North Carolina, providing nonclinical, preclinical, clinical and commercialization services to pharmaceutical and biotechnology industries. Formerly called Covance, the company is part of Labcorp, which employs more than 70,000 people worldwide.

In the life sciences, a contract research organization (CRO) is a company that provides support to the pharmaceutical, biotechnology, and medical device industries in the form of research services outsourced on a contract basis. A CRO may provide such services as biopharmaceutical development, biological assay development, commercialization, clinical development, clinical trials management, pharmacovigilance, outcomes research, and real world evidence.

Cinven Limited is a global private equity firm founded in 1977, with offices in nine international locations in Guernsey, London, New York, Paris, Frankfurt, Milan, Luxembourg, Madrid, and Hong Kong that acquires Europe and United States based corporations, and emerging market firms that fit with their core businesses, and necessitate a minimum equity investment of €100 million or more. As of 2023, it has €39 billion in assets under management.

Parexel International is an American provider of biopharmaceutical services. It conducts clinical trials on behalf of its pharmaceutical clients to expedite the drug approval process. It is the second largest clinical research organization in the world and has helped develop approximately 95% of the 200 top-selling biopharmaceuticals on the market today. The company publishes the annual Parexel R&D Statistical Sourcebook and operates the Parexel-Academy.

IQVIA, formerly Quintiles and IMS Health, Inc., is an American Fortune 500 and S&P 500 multinational company serving the combined industries of health information technology and clinical research. IQVIA is a provider of biopharmaceutical development, professional consulting and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including investment strategy and management consulting services. It has a network of more than 88,000 employees in more than 100 countries and a market capitalization of US$49 billion as of August 2021. As of 2023, IQVIA was reported to be one of the world's largest contract research organizations (CRO).

The University of Cincinnati Academic Health Center (AHC) is a collection of health colleges and institutions of the University of Cincinnati, Cincinnati, Ohio. It trains health care professionals and provides research and patient care. AHC has strong ties to UC Health, which includes the University of Cincinnati Medical Center and West Chester Hospital.

<span class="mw-page-title-main">Select Medical</span> American healthcare company

Select Medical is a healthcare company based in Pennsylvania. It owns long-term acute care and inpatient rehabilitation hospitals, as well as occupational health and physical therapy clinics. Select Medical is a subsidiary of Select Medical Holdings, which is listed on the New York Stock Exchange.

Laboratory Corporation of America Holdings, more commonly known as Labcorp, is an American healthcare company headquartered in Burlington, North Carolina. It operates one of the largest clinical laboratory networks in the world, with a United States network of 36 primary laboratories. Before a merger with National Health Laboratory in 1995, the company operated under the name Roche BioMedical. Labcorp performs its largest volume of specialty testing at its Center for Esoteric Testing in Burlington, North Carolina, where the company is headquartered. As of 2018, Labcorp processes 2.5 million lab tests weekly.

<span class="mw-page-title-main">CCMP Capital</span> American private equity investment firm that focuses on leveraged buyouts

CCMP Capital Advisors, LP is an American private equity investment firm that focuses on leveraged buyout and growth capital transactions. Formerly known as JP Morgan Partners, the investment professionals of JP Morgan Partners separated from JPMorgan Chase on July 31, 2006. CCMP has invested approximately $12 billion in leveraged buyout and growth capital transactions since inception. In 2007, CCMP was ranked #17 among the world's largest private equity funds.

<span class="mw-page-title-main">Stada Arzneimittel</span> German pharmaceutical company

Stada Arzneimittel AG is a pharmaceutical company based in Bad Vilbel, Germany which specializes on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In 2022, revenue totaled €3.79 billion.

WuXi AppTec is a global pharmaceutical, biopharmaceutical, and medical device company.

<span class="mw-page-title-main">Lupin Limited</span> Indian multinational pharmaceutical company

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

<span class="mw-page-title-main">Ohio bioscience sector</span> Significant economic sector in the state

The Ohio bioscience sector strength was ranked #4 among USA states in 2008 by Business Facilities magazine.

Curia is a contract research and manufacturing organization that provides drug discovery, development, cGMP manufacturing and aseptic fill and finish to the pharmaceutical and biotechnology industries. Founded in 1991, Curia operates in the United States, Europe and Asia, with its headquarters located in Albany, New York. Curia has announced deals and collaborations with such companies as Pfizer Inc., Merck & Co., Eli Lilly and Co., Takeda, Genentech, Bristol-Myers Squibb Co. and GE.

<span class="mw-page-title-main">Advanz Pharma</span> British pharmaceutical company

Advanz Pharma Corp. is a British multinational pharmaceutical company headquartered in London. It changed its name from Concordia Healthcare Corp. in November 2018. The company focuses on a number of therapy areas including endocrinology, ophthalmology, urology, anti-infectives, pain management, central nervous system disorders, oncology, haematology, cardiology and intensive care medicine. The company also focuses on acquiring legacy pharmaceutical compounds which are usually off-patent. The operational headquarters is in London, UK, operations centre in Mumbai, India and regional hubs in Europe, Australia and Canada.

WIL Research Laboratories, LLC was a contract research organization (CRO), privately held for 40 years, that provided product safety toxicological research, metabolism, bioanalytical, pharmacological, and formulation services to the pharmaceutical, biotechnology, chemical, agrochemical, and food products industries, as well as manufacturing support for clinical trials. WIL Research was well-known internationally in many disciplines, and considered by many industry experts to be the premier laboratory in the world for developmental and reproductive toxicology (DART).

ICON plc is an Irish headquartered Nasdaq listed multinational healthcare intelligence and clinical research organisation that provides consulting, clinical development and commercialisation services for the pharmaceutical industry. As of June 2023, ICON had approximately 41,160 employees in 108 locations spread across 53 countries.

References

  1. 1 2 3 4 Aycock, Jason (24 June 2016). "Medpace Holdings files to raise up to $150M in IPO". Seeking Alpha. Retrieved 2016-06-26.
  2. ↑ Vinluan, Frank (14 June 2011). "Mid-sized CROs perform as good or better than larger ones, survey says". MedCity News. New York, New York: Breaking Media. Retrieved 31 Aug 2019. The strong performance of mid-sized CROs was evident in the category for speed of site and investigator recruitment. Cincinnati, Ohio-based MedPace was the highest scoring CRO in survey responses for that category while large CROs such as Covance, Parexel, PPD, PRA International and Quintiles all received negative marks.
  3. ↑ "S-1". EDGAR. 24 June 2016. Retrieved 2016-06-26.
  4. 1 2 3 Brunsman, Barrett J. (22 August 2016). "Cincinnati CEO buys $20M worth of stock in IPO". Cincinnati Business Courier. American City Business Journals. Retrieved 31 Aug 2019. After the Aug. 16 transaction, Troendle directly owned more than 1.2 million shares of Medpace.
  5. ↑ Jonathan Isaacsohn M.D., William Insull JR., M.D., Evan Stein M.D.Ph.D., Peter Kwiterovich M.D., Ma Patrick M.D., Ronald Brazg M.D., Carlos A. Dujovne M.D., Michael Shan PH.D., Elizabeth Shugrue-Crowley B.S., Steven Ripa M.D., Robert Tota M.D. (September 2001). "Long-Term Efficacy and Safety of Cerivastatin 0.8 mg in Patients with Primary Hypercholesterolemia". Clinical Cardiology. 24 (Supplement S4): IV1-9. doi:10.1002/clc.4960240902. PMC   6655191 . PMID   11594407.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  6. ↑ Orloff, David. "Interview with Dr. David Orloff". August 23, 2011. Pharmaceutical Business Review. Retrieved 10 April 2013.
  7. ↑ Hirt, Amy. "Courier Contributor". Cincinnati Business Courier. The Business Journals Digital Network. Retrieved 9 April 2013.
  8. ↑ "Medpace Construction Ranks 3rd behind downtown mega projects". April 2010. Retrieved 10 April 2013.
  9. ↑ "Brownfield Redevelopment". cincinnati-oh.gov. Archived from the original on 28 August 2013. Retrieved 9 April 2013.
  10. ↑ "Medpace acquires Czech CRO". Pharma Times. 22 August 2007. Retrieved 10 April 2013.
  11. ↑ "Medpace acquires Symbios Clinical". April 8, 2010. Pharmacy News EU. Retrieved 11 April 2013.
  12. ↑ "Medpace acquires European CRO". January 2010. Retrieved 10 April 2013.
  13. ↑ Morrison, Natalie (20 November 2012). "Medpace boost EU device offering through Meditech takeover". Outsourcing Pharma. Retrieved 11 April 2013.
  14. 1 2 Roumeliotis, Greg (23 February 2014). "Cinven to acquire Medpace in $900 million deal: sources". Reuters. Retrieved 31 Aug 2019.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.